The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s non-alcoholic steatohepatitis biomarkers market report forecasts the non-alcoholic steatohepatitis biomarkers market size to grow to $2.54 Billion by 2027, with a CAGR (compound annual growth rate) of more than 23%.

Learn More On The Non-Alcoholic Steatohepatitis Biomarkers Market Report 2023 – https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report

Non-Alcoholic Steatohepatitis Biomarkers Market Size Forecast
The global non-alcoholic steatohepatitis biomarkers market is expected to grow from $0.88 billion in 2022 to $1.10 billion in 2023 at a compound annual growth rate (CAGR) of 24.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global non-alcoholic steatohepatitis biomarkers market size is expected to grow to $2.54 billion in 2027 at a CAGR of 23.2%.

North America held the largest non-alcoholic steatohepatitis biomarkers market share, and Asia-Pacific was the fastest-growing region in 2022.

Key Non-Alcoholic Steatohepatitis Biomarkers Market Driver ­– Growth In The Prevalence Of Non-Alcoholic Steatohepatitis
According to “The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective,” an article published in The American Journal of Medicine, a US-based peer-reviewed medical journal and the official journal of the Alliance for Academic Internal Medicine, the number of Americans with nonalcoholic fatty liver disease will rise from 83.1 million in 2015 to 100.9 million in 2030 by September 2020. Non-alcoholic steatohepatitis (NASH), decompensated cirrhosis, and hepatocellular carcinoma are expected to increase by 63%, 168%, and 137%, respectively, by 2030. Non-alcoholic steatohepatitis (NASH) can develop from fatty liver disease (NAFLD). As a result, the rising prevalence of non-alcoholic steatohepatitis (NASH) is propelling the non-alcoholic steatohepatitis biomarkers market.

Request for A Sample Of The Global Non-Alcoholic Steatohepatitis Biomarkers Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9002&type=smp

Key Non-Alcoholic Steatohepatitis Biomarkers Market Trend – Technological Advancement
Major companies in the non-alcoholic steatohepatitis biomarkers market are focusing on developing innovative solutions to strengthen their market position. For example, in October 2022, GENFIT, a late-stage biopharmaceutical company based in France, and LabCorp, a life sciences company based in the United States, agreed on a five-year exclusive licencing agreement for GENFIT’s NIS4 technology to aid in the identification of patients with non-alcoholic steatohepatitis at risk (NASH). NIS4 technology is a novel multi-biomarker-based algorithm designed to identify patients with non-alcoholic steatohepatitis (NASH) and significant to advanced fibrosis (F > 2), also known as at-risk NASH. As part of the agreement, LabCorp will develop and commercialise a blood-based molecular diagnostic test based on NIS4 technology in the United States and Canada, allowing healthcare professionals widespread access.

Non-Alcoholic Steatohepatitis Biomarkers Market Segment
1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types
2) By Disease: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
3) By End Use: Research Institutes And Academics, Diagnostic Centres, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses

Non-Alcoholic Steatohepatitis Biomarkers Market Major Players and Strategies
Major players in the non-alcoholic steatohepatitis biomarkers market are Genfit, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Xeptagen SpA, Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, and Allergan PLC.

Novo Nordisk A/S, a Danish pharmaceutical company, will collaborate with Echosens SA in June 2022. With this collaboration, the companies hope to promote early detection of non-alcoholic steatohepatitis (NASH) and raise disease awareness among patients, medical professionals, and other stakeholders. Echosens SA is a therapeutic monitoring and diagnostic device manufacturer based in France.

The Non-Alcoholic Steatohepatitis Biomarkers Global Market Report 2023 covers regional data on non-alcoholic steatohepatitis biomarkers market size, non-alcoholic steatohepatitis biomarkers market trends and drivers, opportunities, strategies, and non-alcoholic steatohepatitis biomarkers market competitor analysis. The countries covered in the non-alcoholic steatohepatitis biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

NASH is a type of liver inflammation and damage caused by a buildup of fat in the liver. NASH biomarkers are used as diagnostic tools to determine the severity of NASH and the extent of liver damage. This causes liver cell damage and inflammation, which can lead to cirrhosis (liver scarring) and liver failure. Biomarkers are specific qualities that can be tested to reveal pathogenic processes, healthy biological processes, or responses to exposure or treatment.

View More Reports Related To The Non-Alcoholic Steatohepatitis Biomarkers Market –
Non Alcoholic – Beverages Global Market Report 2023
Biomarkers Global Market Report 2023
Renal Biomarkers Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: